Download Slides - View the full AIDS 2016 programme

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
microbial translocation
during hyperacute SIV
infection
Adam Ericsen1,2, Michael Lauck3, Mariel Mohns3, Sarah DiNapoli4, James
Mutschler5, Justin Greene3, Jason Weinfurter1, Gabrielle Lehrer-Brey5, Kristin
Crosno5, Eric Peterson5, Matthew Reynolds1, Roger Wiseman1, Benjamin Burwitz6,7,
Jonah Sacha6,7, Thomas Friedrich 5,8, Jason Brenchley4, David O'Connor 1,5
1 University of Wisconsin-Madison, Pathology and Laboratory Medicine, Madison, United States, 2 University of Wisconsin-Madison, Virology
Training Program, Madison, United States, 3 University of Wisconsin-Madison, Madison, United States, 4 National Institute of Allergy and
Infectious Disease, Laboratory of Molecular Microbiology, Bethesda, United States, 5 Wisconsin National Primate Research Center, Madison,
United States, 6 Oregon Health & Sciences University, Vaccine & Gene Therapy Institute, Beaverton, United States, 7 Oregon Health &
Sciences University, National Primate Research Center, Beaverton, United States, 8 University of Wisconsin-Madison, Pathobiological
Sciences, Madison, United States
viremia drives disease
progression
SIV RNA copies/ml
9
8
hypothesis
7
6
the composition of the gut or blood
microbial community differentiates
controllers from progressors.
5
4
3
2
0
7
14
21
28
35
42
days post-infection
[y-axis is log 10-transformed]
49
56
63
70
77
84
91
98 105 112 119 126 133 140
but what drives viremia?
SIV RNA copies/ml
9
hypothesis
8
7
the composition of the gut or blood
microbial communities differentiates
controllers from progressors.
6
5
4
3
2
0
7
14
21
28
35
42
days post-infection
[y-axis is log 10-transformed]
49
56
63
70
77
84
91
98 105 112 119 126 133 140
study design
intrarectal
SIVmac239
-42
0
8
14 18 21 35 56
monitored into
chronic infection
days post-infection
‣ 8 macaques
‣ MHC-identical
(HLA-A & HLA-B)
16S rDNA seq of stool
16S rDNA seq & qPCR of plasma
flow cytometry PBMC (CD4+CCR5+)
plasma analyte ELISA
cynomolgus macaques
rhesus macaques
16S rDNA copies/ml
6
5
4
3
2
1
-5
0
5
10
15
20
Day Post-Infection
days post SIV infection
25
30
35
LPS-binding antibodies (EndoCAb)
soluble CD14
frequency
absolute count
but does microbial translocation increase viremia?
inducing microbial translocation
in macaque elite controllers
water with 0.5% dextran
sulfate sodium (DSS)
administered orally
intrarectal
SIVmac239
+1 year
-35 -21 -14
-7
0
1
2
3
4
…
days post-DSS
treatment
days post-dextran
sulfate
sodium
(DSS) treatment
monitored for
10 weeks
inducing microbial translocation
in macaque elite controllers
Data 2
Data 2
simian immunodeficiency
virus
infection
water with
0.5%
dextran
7
sulfate sodium (DSS)
administered orally
6 intrarectal
SIVmac239
5
4
monitored for
8 weeks
+1 year
3
-35 -21 -14
1
2
3
4
…
days post-infection
days post-DSS
0DSS
330
325
340
-5
320
335
80 120 160 200 240 280 -20 -15 -10
315
330
310
325
305
320
300
315
280
310
240
305
300
200
280
160
240
120
40
200
80
0
160
40
120
0
80
0
days post-DSS treatment
2
40
-7
DSS
6
water with 0.5% dextran
sulfate sodium (DSS)
administered orally
intrarectal
5 SIVmac239
4
+1 year
3
-35 -21 -14
-7
0
1
2
3
4
…
monitored for
8 weeks
Dayssulfate
Post-DSS
days post-dextran
sodium treatment
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
-5
-10
-15
-20
-25
2
-30
days post-DSS treatment
-35
Log10 vRNA copies/ml plasma
inducing microbial translocation
in macaque elite controllers
inducing microbial translocation
in macaque elite controllers
increased plasma levels of
intestinal fatty-acid binding protein
increased plasma
water with 0.5%16S
dextran
rDNA load
sulfate sodium (DSS)
administered orally
intrarectal
SIVmac239
+1 year
-35 -21 -14
-7
0
1
2
3
4
…
days post-DSS treatment
days post-dextran sulfate sodium treatment
monitored for
8 weeks
inducing microbial translocation
in macaque elite controllers
water with 0.5% dextran
sulfate sodium (DSS)
administered orally
intrarectal
SIVmac239
+1 year
-35 -21 -14
-7
0
1
2
3
4
…
days post-DSS treatment
days post-dextran sulfate sodium treatment
monitored for
8 weeks
acknowledgements
‣ AIDS Vaccine Research Laboratory
•
•
•
•
•
•
•
Meghan Breitbach
Ken Drinkwater
Dawn Dudley
Thomas Friedrich
Samantha Gieger
Michael Graham
Justin Greene
•
•
•
•
•
•
•
Julie Karl
Michael Lauck
Gabrielle Lehrer-Brey
Mariel Mohns
James Mutschler
David O’Connor
Trent Prall
‣ Wisconsin National Primate
Research Center
• Kristin Crosno
• Eric Peterson
• Buddy Capuano
‣ NIAID
• Sarah DiNapoli
• Jason Brenchley
•
•
•
•
•
Eva Rakesz
Mustafa Rasheed
Matthew Reynolds
Jason Weinfurter
Roger Wiseman
‣ Oregon Health &
Sciences University
• Benjamin Burwitz
• Jonah Sacha
‣ NCI
• Jacob Estes
‣ Funding
• NIH
• T32 AI078985
Related documents